Cargando…

Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson’s Disease

Continuous dopaminergic stimulation in Parkinson’s disease (PD) has several advantages over pulsatile, non-continuous, stimulation. These therapies currently consist of pump-based and transcutaneous therapies and are based on a more constant delivery of the dopaminergic drug resulting in continuous...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Wamelen, Daniel J., Grigoriou, Sotirios, Chaudhuri, K. Ray, Odin, Per
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311379/ https://www.ncbi.nlm.nih.gov/pubmed/30584160 http://dx.doi.org/10.3233/JPD-181476

Ejemplares similares

Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?
por: Rota, Silvia, et al.
Publicado: (2022)

Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?
por: Chaudhuri, K. Ray, et al.
Publicado: (2013)

Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future
por: Ray Chaudhuri, K, et al.
Publicado: (2016)

Effects of safinamide on pain in patients with fluctuating Parkinson's disease
por: Grigoriou, Sotirios, et al.
Publicado: (2021)

Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
por: Tall, P., et al.
Publicado: (2023)

Cost-Effectiveness of Device-Aided Therapies in Parkinson’s Disease: A Structured Review
por: Smilowska, Katarzyna, et al.
Publicado: (2021)

Covid-19 and Parkinson's disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism
por: Leta, Valentina, et al.
Publicado: (2022)

Implications of dopaminergic medication withdrawal in Parkinson’s disease
por: Koschel, J., et al.
Publicado: (2021)

Personalised Advanced Therapies in Parkinson’s Disease: The Role of Non-Motor Symptoms Profile
por: Leta, Valentina, et al.
Publicado: (2021)

Continuous dopaminergic stimulation (CDS)-based treatment in Parkinson's disease patients with motor complications: A systematic review and meta-analysis
por: Xie, Cheng-long, et al.
Publicado: (2014)

Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?
por: Qamar, MA, et al.
Publicado: (2017)

Viruses, parkinsonism and Parkinson’s disease: the past, present and future
por: Leta, Valentina, et al.
Publicado: (2022)

Is Fitts’ Law Continuous in Discrete Aiming?
por: Sleimen-Malkoun, Rita, et al.
Publicado: (2012)

Disentangling the PIGD classification for the prediction of cognitive impairment in de novo Parkinson’s disease
por: Urso, Daniele, et al.
Publicado: (2021)

Tumoral parkinsonism—Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment
por: Cedergren Weber, Gustav, et al.
Publicado: (2023)

Author Correction: Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?
por: Qamar, M. A., et al.
Publicado: (2023)

Non-motor correlates of wrist-worn wearable sensor use in Parkinson’s disease: an exploratory analysis
por: van Wamelen, Daniel J., et al.
Publicado: (2019)

Clinical trajectories and biomarkers for weight variability in early Parkinson’s disease
por: Urso, Daniele, et al.
Publicado: (2022)

Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study
por: Olanow, C. Warren, et al.
Publicado: (2021)

Parkinson’s disease, dopaminergic drugs and the plant world
por: Kempster, Peter, et al.
Publicado: (2022)

Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson’s Disease
por: van Poppelen, Daniël, et al.
Publicado: (2021)

Parkinson's disease and Covid-19: The effect and use of telemedicine
por: Podlewska, Aleksandra M., et al.
Publicado: (2022)

Drooling in Parkinson’s Disease: Prevalence and Progression from the Non-motor International Longitudinal Study
por: van Wamelen, Daniel J., et al.
Publicado: (2020)

Continuous Integration vs. Continuous Delivery vs. Continuous Deployment
por: Laster, Brent
Publicado: (2020)

Continuous levodopa for advanced Parkinson’s disease
por: Lundqvist, Christofer
Publicado: (2007)

Continuous theta burst stimulation for drug-resistant epilepsy
por: Carrette, Sofie, et al.
Publicado: (2022)

The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
por: Leta, Valentina, et al.
Publicado: (2023)

Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Progranulin Gene Delivery Protects Dopaminergic Neurons in a Mouse Model of Parkinson’s Disease
por: Van Kampen, Jackalina M., et al.
Publicado: (2014)

Malignant syndrome in Parkinson's disease without dopaminergic drug withdrawal
por: Chandran, C. J. Suresh
Publicado: (2008)

Parkinson's disease and dopaminergic neurons
Publicado: (2012)

Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum
por: Leta, Valentina, et al.
Publicado: (2021)

The effect on deep brain stimulation of subthalamic nucleus and dopaminergic treatment in Parkinson disease
por: Lo Buono, Viviana, et al.
Publicado: (2020)

Continuous Delivery in the Wild
por: Hodgson, Pete
Publicado: (2020)

A microfluidic platform for continuous monitoring of dopamine homeostasis in dopaminergic cells
por: Yu, Yue, et al.
Publicado: (2019)

Exploring hyperhidrosis and related thermoregulatory symptoms as a possible clinical identifier for the dysautonomic subtype of Parkinson’s disease
por: van Wamelen, Daniel J., et al.
Publicado: (2019)

Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
por: Mamelak, Mortimer
Publicado: (2018)

Continuous versus discrete robotic feedback for brain-computer interfaces aimed for neurorehabilitation
por: Carino-Escobar, Ruben I., et al.
Publicado: (2023)

Shared functional neural substrates in Parkinson's disease and drug-induced parkinsonism: association with dopaminergic depletion
por: Oh, Se Won, et al.
Publicado: (2020)

EEG Microstates Change in Response to Increase in Dopaminergic Stimulation in Typical Parkinson’s Disease Patients
por: Serrano, J. Ignacio, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0jr9egg384d3sb3mn97gu2fmg9